Assistant Research Professor of Pathology and Genomic Medicine, Academic Institute
Assistant Research Member, Research Institute
Weill Cornell Medical College
Arshad Khan received a PhD in Biotechnology from the University of Pune, Pune, India in September 2009. Following a post-doctoral fellowship in Pathology and Laboratory Medicine at the University of Texas Health Science Center’s McGovern School of Medicine, Dr. Khan was appointed as Assistant Professor of Pathology there in March 2016, with his research focusing on class I and Class II (MHC-I and MHC-II) antigen presentation of bacillus Calmette-Guerin (BCG) in order to improve the efficacy of the BCG vaccine against Mycobacterium tuberculosis.
Dr. Khan joined the Houston Methodist Research Institute as a Research Scientist and Assistant Research Member in January 2019, where he works in the research group of Chinnaswamy Jagannath, PhD. Dr. Khan currently is investigating host/pathogen interaction during tuberculosis infection, with special emphasis on studying the metabolic pathways of Mycobacterium tuberculosis and immune components of host cells during latent infection. For his ongoing research projects, Dr. Khan also continues to characterize and develop experimental animal models that can assist in the discovery of new tuberculosis vaccines and drug therapies.
Dr. Khan’s primary research interest is in the development of novel ex vivo and preclinical animal models to further the discovery of novel anti-tuberculosis vaccines and drug therapies for the treatment of tuberculosis. Current projects include the human MSC-based intracellular model to characterize MTB components involved in acquiring phenotypic drug resistance during dormant infection. Other research projects involve investigation of specific biomarkers and epigenetic signatures that exist on macrophages of TB-resistant and susceptible individuals. Additionally, Dr. Khan is interested in identifying the cellular niches that are involved in harboring latent tuberculosis infection, and the immune system inadequacies that can lead to the reactivation of the Mycobacterium tuberculosis pathogen.
Patent Number: WO/2011/111077, Sep 15 2011